A Study of Nevirapine Used Alone or in Combination With AZT in HIV-1-Infected Children

Inclusion Criteria Concurrent Medication: Allowed: * IV gammaglobulin therapy. * Medications for PCP prophylaxis (e.g., TMP / SMX, dapsone, aerosolized and IV pentamidine). * Fluconazole. Patients must have: * HIV infection. A positive Polymerase Chain Reaction (PCR) is not acceptable as the sole evidence of HIV infection. Three out of five children in each age and dose group must have a serum p24 antigen level of 70 pg/ml or greater and/or a plasma viral titer of 50 TCID/ml or greater prior to study entry. * Ability to be followed by their original trial center for the duration of the trial. * Consent of parent or guardian. Exclusion Criteria Co-existing Condition: Patients with the following symptoms and conditions are excluded: * Lymphocytic interstitial pneumonitis if steroid-dependent or requiring supplemental oxygen or with a pretreatment paO2 \< 70 mm Hg. * Opportunistic or serious bacterial infections within 28 days prior to entry. * Demonstrated intolerance to zidovudine prior to administration of nevirapine (in patients enrolled in the combination therapy phase of the study). * CDC classification of P-2D (secondary infectious diseases) and/or P-2E (secondary cancers). * Pre-existing malignancies. Concurrent Medication: Excluded: * Other approved or investigational antiretroviral agents. * All other investigational agents (except fluconazole). * Glucocorticoids and steroid hormones. * Dicumarol, warfarin, and other anticoagulants. * Digitoxin. * Valproic acid. * Tolbutamide. * Doxycycline. * Chloramphenicol. * Isoniazid. * Phenobarbital and other barbiturates. * Hepatotoxic drugs. Patients with prior participation in this trial are excluded. Prior Medication: Excluded: * More than 6 weeks of prior zidovudine (AZT) therapy or more than 6 weeks of any other antiretroviral therapy. Excluded within 7 days prior to study entry: * AZT (in monotherapy groups only). Excluded within 4 weeks prior to study entry: * Other approved or investigational antiretroviral agents. * All other investigational agents. * Glucocorticoids and steroid hormones. * Dicumarol, warfarin, and other anticoagulants. * Digitoxin. * Valproic acid. * Tolbutamide. * Doxycycline. * Chloramphenicol. * Isoniazid. * Phenobarbital and other barbiturates. Active alcohol or drug abuse to impair compliance with the protocol.